Herzliya, Israel-based cannabis producer InterCure is buying rival medical marijuana company Cann Pharmaceutical, also known as Better, for $35 million (44.4 million Canadian dollars) in stock.
InterCure described Better as a pioneering Israeli medical cannabis multinational operator.
The deal includes Better’s:
- Unique cultivars.
- Cultivation site.
- Intellectual property.
- Commercial operations inside and outside Israel.
The acquisition is expected to close in mid-2022.
InterCure said the acquisition will create “revenue synergies” worth an estimated 50 million Israeli new shekels ($15.7 million) in the upcoming year.
“InterCure and Better’s combined business operations are expected to create a new force in the international cannabis industry that will further accelerate our global expansion plans and opportunities and the consolidation process,” InterCure CEO Alex Rabinovitch said in a statement.
Stay informed with MJBiz Newsletters
MJBiz’s family of newsletters gives cannabis professionals an edge in this rapidly changing industry.
- MJBizDaily: Business news for cannabis leaders in your inbox each morning
- MJBiz Cultivator: Insights for wholesale cannabis growers & vertically integrated businesses
- MJBizCon Buzz: Behind-the-scenes buzz on everything MJBizCon
- MJBiz Retail + Brand: New products, trends and news for cannabis retailers, distributors and marketers
- Hemp Industry Week: Roundup of news from hemp farming to CBD product manufacturing
- And more!
The company did not state which international markets Better operates in.